Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Novo Nordisk continues to fall: Where I am buying the stock

Summary by FXStreet
Novo Nordisk (NVO) had another tough session yesterday, finishing more than 2% lower compared to Friday’s close. The pharmaceutical company behind well-known drugs like Wegovy and Ozempic has struggled throughout the year, and the stock now sits more than 50% below its highs from earlier in 2024.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

FXStreetFXStreet

Novo Nordisk continues to fall: Where I am buying the stock

Novo Nordisk (NVO) had another tough session yesterday, finishing more than 2% lower compared to Friday’s close. The pharmaceutical company behind well-known drugs like Wegovy and Ozempic has struggled throughout the year, and the stock now sits more than 50% below its highs from earlier in 2024.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

FXStreet broke the news in on Tuesday, December 9, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Stock Markets icon

Stock Markets

Denmark icon

Denmark

Denmark Economy icon

Denmark Economy

Business & Markets icon

Business & Markets

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal